Want to see HK:2348 full AI Analyst Report?
2348 Stock Chart & Stats
HK$1.20
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.20
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.98 - HK$1.47
Previous CloseN/A
Volume344.00K
Average Volume (3M)355.07K
Market Cap
HK$1.54B
Enterprise ValueHK$258.31M
Total Cash (Recent Filing)HK$1.58B
Total Debt (Recent Filing)HK$77.51M
Price to Earnings (P/E)6.3
Beta0.34
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.16%
Share Statistics
EPS (TTM)0.14
Shares Outstanding1,505,691,000
10 Day Avg. Volume239,600
30 Day Avg. Volume355,066
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.49
Price to Sales (P/S)1.36
P/FCF Ratio7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage & Strong EquityExtremely low debt and a large equity base give durable financial flexibility: the company can fund R&D, capex, dividends or opportunistic M&A without high interest burden. This conservatism reduces refinancing risk and supports operations through multi-quarter industry cycles.
Healthy Margin ProfileHigh gross and solid operating margins indicate a structurally profitable manufacturing and commercialization model. Durable margins provide a buffer against pricing or cost shocks, underpin long‑term cash generation, and support reinvestment or dividend policy across several quarters.
Improved Cash GenerationMaterial improvement in operating and free cash flow enhances the firm's ability to self‑fund operations, R&D and distributions. Sustained positive FCF over multiple quarters would support capex flexibility and reduce reliance on external financing for strategic initiatives.
Bears Say
Earnings VolatilityA large year‑over‑year earnings swing highlights unstable profitability drivers such as product mix, one‑offs or margin pressure. Persistent earnings volatility complicates forecasting, capital allocation and could constrain sustained investment or dividend commitments over multiple quarters.
Cash‑flow Conversion VariabilityInconsistent conversion of profits into cash creates structural uncertainty around funding durability. Even with strong headline FCF in 2025, variable conversion raises the risk that a downturn or working‑capital swing will force belt‑tightening, affecting R&D, capex or distributions over ensuing quarters.
Declining Return On EquityA marked drop in ROE signals reduced efficiency in generating profits from shareholders' capital. If persistent, weakening ROE can limit the company's ability to justify reinvestment, attract capital, or sustain payout ratios, pressuring long‑term growth prospects.
Dawnrays Pharmaceutical Holdings Ltd. News
2348 FAQ
What was Dawnrays Pharmaceutical Holdings Ltd.’s price range in the past 12 months?
Dawnrays Pharmaceutical Holdings Ltd. lowest stock price was HK$0.98 and its highest was HK$1.47 in the past 12 months.
What is Dawnrays Pharmaceutical Holdings Ltd.’s market cap?
Dawnrays Pharmaceutical Holdings Ltd.’s market cap is HK$1.54B.
When is Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date?
Dawnrays Pharmaceutical Holdings Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 50 days.
How were Dawnrays Pharmaceutical Holdings Ltd.’s earnings last quarter?
Dawnrays Pharmaceutical Holdings Ltd. released its earnings results on Mar 27, 2026. The company reported HK$0.08 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.08.
Is Dawnrays Pharmaceutical Holdings Ltd. overvalued?
According to Wall Street analysts Dawnrays Pharmaceutical Holdings Ltd.’s price is currently Overvalued.
Does Dawnrays Pharmaceutical Holdings Ltd. pay dividends?
Dawnrays Pharmaceutical Holdings Ltd. pays a Annually dividend of HK$0.048 which represents an annual dividend yield of 5.16%. See more information on Dawnrays Pharmaceutical Holdings Ltd. dividends here
What is Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate?
Dawnrays Pharmaceutical Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dawnrays Pharmaceutical Holdings Ltd. have?
Dawnrays Pharmaceutical Holdings Ltd. has 1,505,691,000 shares outstanding.
What happened to Dawnrays Pharmaceutical Holdings Ltd.’s price movement after its last earnings report?
Dawnrays Pharmaceutical Holdings Ltd. reported an EPS of HK$0.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.791%.
Which hedge fund is a major shareholder of Dawnrays Pharmaceutical Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:2348
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dawnrays Pharmaceutical Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.03%
12-Months-Change
Fundamentals
Return on Equity
6.40%
Trailing 12-Months
Asset Growth
4.66%
Trailing 12-Months
Company Description
Dawnrays Pharmaceutical Holdings Ltd.
Dawnrays Pharmaceutical (Holdings) Limited operates as an investment holding company, primarily engaged in the creation, production, and global distribution of generic pharmaceutical medicines, with a focus on Mainland China and international markets. Its operations are divided into two main divisions: Intermediates and Bulk Medicines, and Finished Drugs. The company's diverse product portfolio features a range of antibiotics, including pharmaceutical intermediates, bulk active ingredients, powdered formulations for injection, and oral antibiotic preparations. Furthermore, Dawnrays offers specialized medications addressing various bodily systems and conditions, such as those for cardiovascular health, allergies, Hepatitis B Virus (HBV), digestive and urinary issues, antipyretic-analgesic (fever and pain relief), respiratory ailments, and endocrine disorders. These system-specific drugs are dispensed in familiar forms like tablets, capsules, and granules. Founded in 1995, the firm maintains its headquarters in Wan Chai, Hong Kong, and is a subsidiary of Fortune United Group Limited.
Technical Analysis
Lee's Pharmaceutical Holdings Limited
―
Fusen Pharmaceutical Co., Ltd.
―
JBM (Healthcare) Ltd.
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―
Options Prices
Currently, No data available
---